No Detail Found!

Expression of Matrix Metalloproteinase-1 (MMP1) in Breast Cancer: Integrative Survival Analysis of Tumor Characteristics and Clinical Outcomes

Author(s)
Naglaa Ahmed Bayomy Department of Anatomy, College of Medicine, Northern Border University, Arar, Saudia Arabia
Afaf Taha Ibrahiem Department of Pathology, Faculty of Medicine, Mansoura University, Egypt, Mansoura City-35516, Egypt
Aziza Ali Alenezi University Health Center, Northern Border University, Arar, Saudia Arabia
Anshoo Agarwal Department of Pathology, College of Medicine, Northern Border University, Arar, Saudi Arabia
Ahmed M. Hegazy Department of Anatomy, College of Medicine, Northern Border University, Arar, Saudia Arabia
Nawal Salama Gouda Department of Microbiology, College of Medicine, Northern Border University, Arar, Saudia Arabia
Wajid Ali Chatha Department of Anatomy, College of Medicine, Northern Border University, Arar, Saudia Arabia
Shaimaa M. Yussif Department of Pathology, Faculty of Medicine, Mansoura University, Egypt, Mansoura City-35516, Egypt
Abdelnaser Badawy Department of Medical Biochemistry, College of Medicine, Northern Border University, Arar, Saudi Arabia
Marwa S. Badawi Department of Anatomy, College of Medicine, Northern Border University, Arar, Saudia Arabia
Naglaa Mokhtar Department of Medical Biochemistry, College of Medicine, Northern Border University, Arar, Saudi Arabia ; Department of Medical Biochemistry, Faculty of Medicine, Mansoura University, Mansoura City-35516, Egypt
Saad Elshafey Department of Anatomy, College of Medicine, Northern Border University, Arar, Saudia Arabia
Rashad Qasem Ali Othman Department of Pathology, College of Medicine, Northern Border University, Arar, Saudi Arabia
Elryah. I. Ali Department of Medical Laboratory Technology, College of Applied Medical Sciences, Northern Border University, Arar, Saudi Arabia
Nader Elmalki Department of Internal Medicine, Faculty of Medicine, Jouf University, Sakaka City, Saudi Arabia
Abstract
Background: Breast cancer is the most frequently diagnosed cancer type and the second leading cause of cancerrelated deaths among women worldwide. Following a diagnosis of breast cancer, the most immediate challenges in patient management are the determination of prognosis and identification of the most appropriate adjuvant systemic therapy. Determining prognosis can best be addressed with a combination of clinicopathological prognostic factors. Methods: A retrospective study was performed on paraffin blocks of Breast carcinoma, histopathological findings were reviewed and recorded, Immunohistochemistry (IHC) for Matrix Metalloproteinase-1 (MMP1) proteins were performed. The investigation incorporated key clinical variables including hormone receptor status (Estrogen Receptor (ER) and Progesterone Receptor (PR), human epidermal growth factor receptor 2 (HER2) expression, tumor laterality, focality and pathological grade. Results: Statistical analyses encompassed descriptive statistics, correlation analysis, Cox proportional hazards regression and survival curve estimation using Kaplan-Meier methodology revealed strong intercorrelations between survival metrics and identified matrix MMP1 as a significant negative prognostic indicator across all survival endpoints. Chi-square analysis demonstrated significant association between HER2 and ER status, suggesting distinct biological subtypes with varying therapeutic implications. Conclusion: This study identifies MMP1 as a potent independent prognostic marker for poor survival in breast cancer. The results advocate for the integration of MMP1 assessment with standard biomarker profiling to enhance prognostic accuracy and inform clinical decision-making for personalized patient management.
Publication Details
Page(s) 182-193
DOI DOI not available
Published Journal: Journal of Pioneering Medical Sciences, Volume: 15, Issue: 1, Year: 2026

Request the full text from PASTIC

Keywords
Tumor Characteristics, MMP1, clinical outcomes, Survival analysis, Prognostic factors, Breast Cancer
References
Siegel R.L. .2017 .A Cancer Journal for Clinicians. , 67 : 7-30.
Boire A. .2004 .PAR1 Is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. ” Cell, 12 : 303-313.
Carlson R.W. .2012 .Featured Updates to the NCCN Guidelines. ” Journal of the National Comprehensive Cancer Network, 10 : 821-829.
Beeghly-Fadiel A. .2009 .No association between matrix metalloproteinase-1 or matrix metalloproteinase-3 polymorphisms and breast cancer susceptibility. Biomarkers & Prevention, 09 : 1055-9965.
Slattery M.L. .2013 .Matrix Metalloproteinase Genes Are Associated with Breast Cancer Risk and Survival. ” PLOS One, 8 : .
Tower G.B. .2003 .The 2G Single Nucleotide Polymorphism in the MMP-1 Promoter Contributes to High Levels of MMP1 Transcription.” Breast Cancer Research and Treatment. , 0000003948 : 75-82.
Zhou J. .2011 .. Analysis of Matrix Metalloproteinase-1 Gene Polymorphisms and Expression in Breast Tumors.” Cancer Investigation, 29 : 599-607.
Amin M. . .A Cancer Journal for Clinicians. , 67(2017) : 93-99.
Pallant J. SPSS Survival,Manual J. SPSS Survival .2020 .. , : .
Jezequel P. .2012 .bc-GenExMiner: An Easy-to-Use Online Platform for Gene Prognostic Analyses. Breast Cancer Research and Treatment, 131 : 765-775.
Jezequel P. .2013 .. bc-GenExMiner 3, : .
Genome Atlas Network Cancer .2012 .. Comprehensive Molecular Portraits of Human Breast Tumours.” Nature, 490 : 61-70.
Gao J. .2013 .. Integrative Analysis of Complex Cancer Genomics Using cBioPortal.” Science Signaling, 6 : .
Cerami E. . .. The cBio Cancer Genomics Portal.” Cancer Discovery, 12(2012) : 2159-8290.
Visse R.,Nagase R.,Inhibitors Tissue .2003 .Matrix Metalloproteinases. Circulation Research, 0000070112(8) : 827-839.
Xuan J. .2015 .. Matrix Metalloproteinase-1 Expression in Breast Cancer.” Biomedical Reports, 3(3) : 395-397.
McGranahan N.,Swanton C.,Evolution Tumor .2017 .. Cell, 01 : 613-628.
Savas P. .2015 .Clinical Relevance of Host Immunity in Breast Cancer. Nature Reviews Clinical Oncology, 13 : 228-241.
Waks A.G.,Winer E.P. .2018 .Breast cancer treatment: A review. ” JAMA, 321 : 288-300.
Harbeck N.,Gnant M. .2017 .Breast cancer. The Lancet, 6736(16) : 31891-8.
Wu X. .2024 .Prognostic significance of ER-to-PR difference. ” Scientific Reports, 14 : .
Zhou Z. .2018 .. polymorphism and cancer Risk.” Disease Markers, : MMP1.
Decock J. .2011 .Matrix metalloproteinases: Protective roles in cancer. ” Journal of Cellular and Molecular Medicine, 01302 : 4934-1265.
Cui N. .2017 .Biochemical and biological attributes of matrix metalloproteinases. ” Progress in Molecular Biology and Translational Science, 02 : 1-73.
Gyorffy B. .2010 .Online survival analysis tool. Breast Cancer Research and Treatment, 123 : 725-731.
Tsang J.Y.S.,Tse G.M. “ .2020 .Molecular classification of breast cancer. ” Advances in Anatomic Pathology, 27 : 27-35.
Mook S. .2009 .Calibration and accuracy of prognosis calculation. The Lancet Oncology, 09 : 70254-2.
Gialeli C. .2010 .Roles of matrix metalloproteinases in cancer progression. ” FEBS Journal, 07919 : 4658-27.
Denkert C. .2018 .Tumour-Infiltrating lymphocytes and prognosis. The Lancet Oncology, 17 : 30904-50.
Poola I. .2005 .Identification of MMP-1 as a breast cancer marker. ” Nature Medicine, 11(5) : 481-483.
Kousidou O.C.,NovemberDecember O.C. .2004 .Expression of MMPs and TIMPs genes. Anticancer Research, 24(6) : 4025-4030.
Wolff A.C. .2018 .HER2 testing in breast cancer. ” Journal of Clinical Oncology, 77(20) : 2105-2122.
Kurnia I. .2022 .Molecular Patho-mechanisms of Cervical Cancer (. ” Annals of Medicine and Surgery, 77 : .
0

Citations

0

Downloads

19

Views